E3 PreliminaryPreliminaryPEM not requiredMechanisticPeer-reviewedMachine draft
Early Growth Response Gene Upregulation in Epstein-Barr Virus (EBV)-Associated Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).
Kerr, Jonathan · Biomolecules · 2020 · DOI
Quick Summary
This study looked at specific genes called EGR genes that turn on in response to stress and infection. Researchers found that these genes were abnormally active in blood samples from some ME/CFS patients, and this activity matched up with signs of Epstein-Barr virus (EBV) reactivation. This suggests that in some people with ME/CFS, a dormant virus may be waking up and triggering an ongoing immune response.
Why It Matters
Understanding whether EBV reactivation drives ME/CFS symptoms in some patients could open new diagnostic and treatment approaches, potentially offering antiviral or immune-modulating therapies to a subset of sufferers. This work supports the biological plausibility of ME/CFS as a disease with measurable molecular abnormalities rather than a purely psychological condition.
Observed Findings
- EGR1, EGR2, and EGR3 expression was upregulated in blood from a subset of ME/CFS patients
- Upregulation of EGR genes closely paralleled upregulation of EBI2 (an EBV-induced gene)
- The pattern suggests ongoing EBV reactivation in some—but not all—ME/CFS patients
- EGR genes regulate multiple biological processes relevant to ME/CFS including immune function, vascular homeostasis, and mitochondrial function
Inferred Conclusions
- EBV reactivation may be an active biological process in a subset of ME/CFS patients, detectable through coordinated upregulation of viral and cellular genes
- EGR gene upregulation provides molecular evidence supporting the role of persistent viral activation in ME/CFS pathophysiology
- The overlap between EGR functions and ME/CFS-relevant pathways (immunity, vascular function, mitochondrial processes) suggests a potential mechanism linking viral reactivation to disease manifestations
Remaining Questions
- Which ME/CFS patients have EBV reactivation versus other causes, and can this distinction predict treatment response?
- Do EGR genes drive ME/CFS symptoms through viral reactivation, or is abnormal EGR expression an independent problem?
- Can antiviral or immunomodulatory treatments targeting EBV reactivation improve outcomes in EGR-upregulated ME/CFS patients?
What This Study Does Not Prove
This study does not prove that EBV reactivation causes ME/CFS or that treating EBV will cure the disease. Finding correlated gene expression does not establish causation, and the study only examined a subset of patients—many ME/CFS patients may not have elevated EGR gene expression. The clinical significance of these molecular findings for individual patients remains unclear.
Tags
Biomarker:Gene ExpressionBlood Biomarker
Phenotype:Infection-Triggered
Method Flag:Weak Case DefinitionExploratory Only
Metadata
- DOI
- 10.3390/biom10111484
- PMID
- 33114612
- Review status
- Machine draft
- Evidence level
- Early hypothesis, preprint, editorial, or weak support
- Last updated
- 7 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →